Erwan Jouannot Selected Research

Radiotherapy

4/2013

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erwan Jouannot Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 04/2013
2	Breast Neoplasms (Breast Cancer) 06/2020 - 01/2020
1	Leukemia 01/2021
1	Bacterial Infections (Bacterial Infection) 04/2015
1	Squamous Cell Carcinoma of Head and Neck 04/2013

Drug/Important Bio-Agent (IBA)

1	Bispecific AntibodiesIBA 01/2021
1	Immunoglobulin Fc FragmentsIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2020
1	palbociclibIBA 06/2020
1	Biomarkers (Surrogate Marker)IBA 06/2020
1	Estrogen ReceptorsIBA 06/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	MucinsIBA 01/2020
1	AntigensIBA 01/2020
1	MaltoseIBA 04/2015
1	PlatinumIBA 04/2013
1	AC 7700IBA 04/2013
1	Cisplatin (Platino)FDA LinkGeneric 04/2013
1	Cetuximab (Erbitux)FDA Link 04/2013

Therapy/Procedure

3	Therapeutics 01/2020 - 04/2013
1	Drug Therapy (Chemotherapy) 01/2020
1	Radiotherapy 04/2013